The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Clinical Cancer Research|2021Cited by 44
LARP1 isoform expression in human cancer cell linesHagen Schwenzer, Sarah P. Blagden, Mai Abdel Mouti et al.|RNA Biology|2020Cited by 18
LARP1 haploinsufficiency is associated with an autosomal dominant neurodevelopmental disorderJames Chettle, Sarah P. Blagden, Megan Li et al.|Human Genetics and Genomics Advances|2024Cited by 5
Abstract 931: From bench to bedside: Using ProTide chemistry to transform 3'-deoxyadenosine into the novel anti-cancer agent Nuc-7738Hagen Schwenzer, Sarah P. Blagden, Mustafa Elshani et al.|Cancer Research|2021Cited by 1
LARP1 regulates metabolism and mTORC1 activity in cancerJames Chettle, Sarah P. Blagden, Colin R. Goding et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1